|
Sign In to gain access to subscriptions and/or personal tools.
|
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
John JV McMurray
CRI in Heart Failure, Wolfson Building, University of Glasgow, Glasgow, G12 8QQ, UK, j.mcmurray{at}bio.gla.ac.uk
Key Words: angiotensin II • antagonists • receptor • heart failure • clinical trials
References
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35.[Abstract]
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
- Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.[Abstract/Free Full Text]
- Packer M., Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;341:709-17.
- Pitt B., Zannad F., Remme WJ et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study. NEnglJMed 1999;100:2312-8.
- Pitt B., Chang P., Timmermans PBM. Angiotensin-II receptor antagonists in heart failure - Rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular Drugs and Therapy 1995;9:693-700.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pitt B., Segal R., Martinez FA, Meurers G., Cowley AJ, Thomas I. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pitt B., Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-54.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -- the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tsuyuki RT, Yusuf S., Rouleau JL et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Card 1997;13:1166-74.
- McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.[Abstract/Free Full Text]
- Cohn JN, Tognoni G., Glazer RD, Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-60.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wolny A., Clozel JP, Rein J. et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circulation Research 1997;80:219-27.[Abstract/Free Full Text]
- Voors AA, Pinto YM, Buikema H. et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028-32.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Petrie MC, Padmanabhan N., McDonald JE, Hillier C., Connell JMC, McMurray JJV. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-61.[Abstract/Free Full Text]
- Siragy HM, Carey RM Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2001;1:99-103.
- Berry C., Norrie J.,McMurray J. Are Angiotensin II receptor blockers more efficacious than placebo in heart failure? implications of ELITE-2. Am J Cardiol 2001;87:606-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Horton R. From star signs to trial guidelines. Lancet 2000; 55:1033-4.
- Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial - VALIANT: rationale and design. Am Heart J 2000;140:727-50.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Swedberg K., Pfeffer M., Granger C. et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;3:5276-82.
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2,
89-92 (2001)
DOI: 10.3317/jraas.2001.017
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau
Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?
Circulation,
November 16, 2004;
110(20):
3281 - 3288.
[Full Text]
[PDF]
|
|
|
|
|
